Evidence map›Paper›PMID 35741298›Full record

ReviewDiagnostics (Basel, Switzerland)2022

A Survey on Deep Learning for Precision Oncology.

Ching-Wei Wang, Muhammad-Adil Khalil, Nabila Puspita Firdi

Abstract readReview
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ching-Wei WangGraduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei 106335, Taiwan.ORCID 0000-0001-9992-6863
Muhammad-Adil KhalilGraduate Institute of Applied Science and Technology, National Taiwan University of Science and Technology, Taipei 106335, Taiwan.
Nabila Puspita FirdiGraduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei 106335, Taiwan.ORCID 0000-0002-3068-8198

Funding

Ministry of Science and Technology, Taiwan MOST 109-2221-E-011-018-MY3
6 · The paper itself

Abstract

Precision oncology, which ensures optimized cancer treatment tailored to the unique biology of a patient's disease, has rapidly developed and is of great clinical importance. Deep learning has become the main method for precision oncology. This paper summarizes the recent deep-learning approaches relevant to precision oncology and reviews over 150 articles within the last six years. First, we survey the deep-learning approaches categorized by various precision oncology tasks, including the estimation of dose distribution for treatment planning, survival analysis and risk estimation after treatment, prediction of treatment response, and patient selection for treatment planning. Secondly, we provide an overview of the studies per anatomical area, including the brain, bladder, breast, bone, cervix, esophagus, gastric, head and neck, kidneys, liver, lung, pancreas, pelvis, prostate, and rectum. Finally, we highlight the challenges and discuss potential solutions for future research directions.

Indexed as

cancer treatmentdeep learningprecision oncologyreviewtherapytreatment planning

Identifiers

PMID35741298
PMCPMC9222056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.